Shanghai Juncell Therapeutics is the lead sponsor of 16 current clinical trials in our China register. 15 are recruiting patients now. The most common phase is Phase EARLY_PHASE1. The drugs named most often in its trials are Tumor Infiltrating Lymphocytes, Autologous Tumor Infiltrating Lymphocytes and GC203 TIL. The most-studied condition is Treatment Side Effects.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
A Study of GC101 TIL in Advanced Melanoma (10hospital)
NCT05098184 · ClinicalTrials.gov ↗ · Advanced Melanoma, Tumor Infiltrating Lymphocyte, Treatment Side Effects
|
Phase EARLY_PHASE1 | Recruiting | 2021-09 | China |
|
A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
NCT05142475 · ClinicalTrials.gov ↗ · Breast Cancer, Treatment Side Effects, Advanced Breast Cancer
|
Phase EARLY_PHASE1 | Recruiting | 2021-11 | China |
|
A Phase II Study of GC101 in NSCLC
NCT07560111 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer
|
Phase 2 | Recruiting | 2026-06 | China |
|
A Study of GC203 TIL in PDCA (RJ)
NCT06828328 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Pancratic Ductal Adenocarcinoma, Treatment Side Effects
Drug: GC203 TIL |
Phase EARLY_PHASE1 | Recruiting | 2025-02 | China |
|
A Study of GC201 TIL in Advanced Gynecologic Tumors (10hospital)
NCT05098171 · ClinicalTrials.gov ↗ · Advanced Gynecologic Tumors, Signal Switch Receptor Modified TIL, Treatment Side Effects
|
Phase EARLY_PHASE1 | Recruiting | 2021-09 | China |
|
Study of GC101 TIL in Brain Glioma (Soochow2)
NCT04943913 · ClinicalTrials.gov ↗ · Glioma
|
Phase EARLY_PHASE1 | Recruiting | 2021-05 | China |
|
A Study of TIL in Advanced Solid Tumors (DFGD)
NCT06488950 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects
Drug: GC203 TIL |
Phase EARLY_PHASE1 | Recruiting | 2023-04 | China |
|
A Study of GC203 TIL in Advanced Solid Tumors (NF)
NCT07256756 · ClinicalTrials.gov ↗ · Solid Tumors, Adult
Drug: GC203 TIL |
Phase 1 | Recruiting | 2026-01 | China |
|
A Study of GC101 TIL in Advanced Melanoma
NCT06703398 · ClinicalTrials.gov ↗ · Melanoma
|
Phase 2 | Recruiting | 2024-12 | China |
|
A Study of GC101 TIL in Advanced Hepatobiliary-Pancreatic Cancers (10hospital)
NCT05098197 · ClinicalTrials.gov ↗ · Advanced Liver Cancers, Tumor Infiltrating Lymphocyte, Treatment Side Effects
|
Phase EARLY_PHASE1 | Recruiting | 2021-09 | China |
|
A Study of GC101 TIL in Advanced Solid Tumors (TR)
NCT04967833 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
|
Phase EARLY_PHASE1 | Recruiting | 2021-04 | China |
|
A Study of GC203 TIL in Advanced Malignant Solid Tumors
NCT06375187 · ClinicalTrials.gov ↗ · Solid Tumor, Gynecologic Cancer, Breast Cancer
|
Phase 1 | Recruiting | 2024-05 | China |
|
A Clinical Study on TIL for the Treatment of Advanced Solid Tumors
NCT05087745 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Tumor Infiltrating Lymphocytes, Treatment Side Effects
|
Phase EARLY_PHASE1 | Recruiting | 2021-12 | China |
|
A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital)
NCT04960072 · ClinicalTrials.gov ↗ · Gastrointestinal Tumor
|
Phase EARLY_PHASE1 | Recruiting | 2021-06 | China |
|
A Phase Ib Study of GC101 in NSCLC
NCT06473961 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer
|
Phase 1 | Recruiting | 2024-10 | China |
|
A Study of TIL in Advanced Solid Tumors (CZ)
NCT07294872 · ClinicalTrials.gov ↗ · Solid Tumor, Adult
|
Phase 1 | Not yet open | 2026-12 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 16 | 15 |
A trial with sites in more than one country appears in each of those registers.
Shanghai Juncell Therapeutics is the lead sponsor of 16 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 15 of its 16 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 4 drugs and biologicals as interventions. The most frequent are Tumor Infiltrating Lymphocytes (5), Autologous Tumor Infiltrating Lymphocytes (3), GC203 TIL (3) and Cisplatin (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.